Medicines - MOP
AIMOVIG® - erenumab
COSENTYX® - secukinumab in Dermatology
COSENTYX® - secukinumab in Rheumatology
ENTRESTO® - sacubitril/valsartan
FABHALTA®▼ - iptacopan
ILARIS® - canakinumab
JAKAVI® - ruxolitinib
KESIMPTA®▼ - ofatumumab
KISQALI® - ribociclib
LEQVIO®▼ - inclisiran
MAYZENT®▼ - siponimod
MEKINIST - trametinib
SANDOSTATIN® LAR® - octreotide acetate
SCEMBLIX®▼ - asciminib
TAFINLAR - dabrafenib
XOLAIR® - omalizumab in Dermatology
Xolair® - omalizumab in Respiratory and Inflamation

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. ▼ The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side-effects you may get. Please see www.mhra.gov.uk/yellowcard. for instructions on how to report side-effects.

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side-effects you can help provide more information on the safety of your medication.


Source URL: https://www.pro.novartis.com/uk-en/public/medicines